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Background: Praziquantel (PZQ) is the drug of choice for treatment of all human schistosomes. It is used in
population based targeted or mass deworming strategies in several countries. The effect of PZQ on S. hematobium
has not been studied in Ethiopia. The objective of this study was to determine the efficacy of PZQ against S.
haematobium in Dulshatalo village, western Ethiopia.
Methods: A prospective study was conducted from October to December, 2007. Urine samples from 341 residents
were collected and screened for haematuria and proteinuria using urinalysis dipstick. S. haematobium eggs were
detected and quantified using filtration techniques. The participants who were positive for haematuria were treated
with a standard dose of PZQ (40 mg/kg). Data on pre and 24 hours post treatment symptoms were collected via
questionnaire. Urine samples were also collected 7 weeks after treatment and examined to assess the cure and the
egg reduction rates.
Results: The prevalence of S. haematobium among the study participants was 57.8% (197/341). Haematuria was
detected in 234 (68.6%) of the study participants. For PZQ efficacy asessment, 152 of the treated participants were
considered. The presence of S. haemetaobium eggs showed statistically significant association (p < 0.05) with
haematuria and proteinuria. Seven weeks post treatment, the extent of haematuria and proteinuria decreased from
100% to 40.8% and 94.07% to 48.7%, respectively. The cure and the parasitological egg reduction rates seven weeks
post treatment were 86% and 85%, respectively. Post treatment symptoms revealed a wide range of side effects
including straining, abdominal pain, nausea and headache.
Conclusions: There were marked cure and egg reduction rates, together with mild and short lived side effects of
PZQ for treatment of S. haematobium, in this study.
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Schistosomiasis is the second most prevalent tropical
disease next to malaria in the world. It affects about 200
million people worldwide with more than 650 million
people living in endemic areas [1-3]. A recent survey in
sub-Sahara Africa indicates that 70 million individuals
out of 682 million have experienced haematuria with 32
million cases of dysuria associated with S. haematobium* Correspondence: birhanuasaye@gmail.com
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distribution, and reproduction in any mediuminfection. Furthermore, it was estimated that 18 million
people suffer from S. haematobium-related bladder wall
pathology and 10 million from hydronephrosis [3]. In
Ethiopia, Schistosoma haematobium is found in the mid-
dle, lower Awash [4], lower Wabe Shebelle valleys [5]
and Kumruk on the Ethio-Sudanese border [6].
Schistosomiasis can be controlled via chemotherapy,
snail control, improved sanitation, and health education.
Currently, a population based target/mass chemotherapy
with Praziquantel (PZQ) is a major controlling strategy
in several countries [7-9]. PZQ is the drug of choice for
schistosomiasis control due to its effect on the adulttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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imal side effects [10-12], easy administration and toler-
ability [13-15]. On the other hand, it lacks efficacy
against the immature stages of schistosomes which is
thought to be a risk for resistance development [16].
The efficacy of PZQ on schsitosomes has been studied
in many countries. Most of the studies made are on its ef-
ficacy in the treatment of S. mansoni and have reported
different cure and egg excretion reduction rates [17-26].
In the treatment of S. haematobium, low cure rates are
reported from Ghana [27] and Senegal [28], while higher
cure and egg reduction rates are obtained from Côte
d'Ivoire [29], Cameroon [30], Zimbabwe [31] and South
Africa [32]. The explanations forwarded for this variation
in efficacy includes the issue of drug resistance [19], and
presence of pre-patent infections existing at the time of
treatment [33] in high transmission areas and the inad-
equacy of single dose of 40 mg/kg under conditions of ex-
tremely high intensity of S. haematobium infection [33].
Side effects due to PZQ usually occur in a relatively lar-
ger population of patients (30-60%) but they are mild and
transient and disappear within 24 hrs [14,25]. Dizziness,
bloody or mucoid diarrhoea and abdominal pain are most
frequently encountered following the treatment of infec-
tions with S. mansoni in studies conducted in Cotedivore,
Uganda and North-East Ethiopia [22,23,25,29]. Vomiting,
weakness and head ache are reported from North-East
Ethiopia [25]. On the other hand, uncommon side effects
such as joint pains, joint swellings, and myalgia and peri-
tibial/ankle oedema are observed following treatment of S.
haematobium in Afar Region, eastern Ethiopia [34].
Monitoring of PZQ efficacy in different areas, where the
drug is widely used is important. This is because of the ab-
sence of alternative drug for the effective treatment of
schistosomiais, the presence of genetic differences in the
schistosome strains and diverse reports in efficacy of
the drug world-wide. In Ethiopia, PZQ is used for the
treatment of cestodes and trematodes at different re-
gimen. It is also used in mass treatment of school chil-
dren and the community. However, the efficacy of PZQ
against Ethiopian strain at different foci is not well investi-
gated. Therefore, the efficacy of PZQ was researched in
Dulshatalo village, one of the urinary schistosomiasis en-
demic areas in Ethiopia.
Methods
Study design, area and period
A prospective study was conducted from October to
December, 2007 in Dulshatalo, a village located about
878 Km west of Addis Ababa and near Ethio-Sudanese
border. Dulshatalo is one of the urinary schistosomiasis
endemic areas in Ethiopia. It is 800 m above sea level
and has population of 801 people [35]. Most of the resi-
dents lived in the area since birth and are involved intraditional gold mining. There are two water bodies in
the village: a pond and a stream. The people are mostly
dependent on these sources of water for bathing, laundry
and traditional gold mining activities.
Sample size and sampling techniques
Sample size was not determined. All of the residents
were summoned for urine examination. Three hundred
forty one of them presented themselves for screening.
Data collection and measurement
Urine collection and analysis
Initially the socio-demographic and clinical data were
collected from study participants. Then, they were given
a wide, clean, labeled container to provide terminal urine
between 10.00 a.m. and 2.00 p.m. Since haematuria is
the best indicator of urinary schistosomiasis in an en-
demic area [8], the participants were tested on the spot
using reagent strips (URS-11, Teco diagnostics, USA).
Preserved in 0.2 ml of 37% formalin, the urine samples
transported to Aklilu Lemma Institute of Pathobiology
(ALIPB) laboratory and then examined, using filtration
technique for S. haematobium eggs. The intensity of in-
fection was assessed according to guideline developed by
Montresor et al. [8]. To assess the cure and the egg re-
duction rates [8], urine samples were collected from the
study participants whose urine samples were positive for
ova of S. haematobium before treatment, who were
treated with PZQ and who were able to report for re-
examination, seven weeks post-treatment.
Treatment
The study participants were treated with single dose of
PZQ (Biltricide®, Bayer AG, Germany), 40 mg/kg body
weight which is a standard treatment dose in Ethiopia.
Clinical diagnosis
compliance about symptoms and side effects of the
drug were collected pre and 24 hrs post treatment,
using questionnaires.
Data analysis
Data from the questionnaire and parasitological study
were double entered into excel. Statistical analysis was
done using STATA Version 8.1(Stata Corporation, Col-
lege station, Texas, USA). Simple frequency and pro-
portions were used to describe the data. Chi-square (for
categorical variables) and correlation (for continuous vari-
ables) were used to evaluate associations. Values were con-
sidered statistically significant when p-value < 0.05 at 95%
confidence interval.
The cure rate was the proportion of S. haematobium
infected patients who had no egg excretion six weeks
after treatment.
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in the intensity of infection assessed indirectly, using egg
count via the following formula (8):
% egg=10 ml reduction ¼ ð1−Geometric mean of eggs=10 ml
urine after treatmentÞx 100 Geometric mean
of eggs=10 ml urine before treatment
Ethical consideration
Ethical clearance was obtained from Ethical Clearance
Committee of ALIPB, Addis Ababa University. The
study participants involved in the study after they
had given their informed consent. For the participants
younger than 18 years, consent was obtained from
their parents or guardians.
Results
Study participants
A total of 341 participants (72.14% male) were involved
at the initial screening of urine. Their age ranged from 2
to 60 years, with a median and a mean of 15 and
19 years, respectively. For PZQ efficacy study, 152 par-
ticipants were enrolled, of whom 123 (80.9%) were male.Table 1 Prevalence and Intensity of S. haematobium based on
village, western Ethiopia





















Total 341 149Their age rangedfrom 2 to 60 years with a median and a
mean of 13 and 16 years, respectively.
Prevalence and intensity of S. haematobium
The overall prevalence of S. haematobium among the
study participants was 57.8% (197/341), with an overall
geometric egg count of 15.32 (Table 1). The presence
of S. haematobium eggs was significantly associated
with age (x2 = 20.12, p = 0.003), haematuria (x2 = 63.83,
p < 0.001), and proteinuria (x2 = 32.94, p < 0.001) (Table 1),
but not with sex (Table 1). In addition, the presence of S.
haematobium eggs in urine was correlated with the degree
of haematuria (r = 0.2108, p = 0.0001) and of proteinuria
(r =0.2171, p = 0.0001).
S. haematobium infections before and after seven weeks
of treatment with PZQ
Of the 152 participants treated with PZQ, 132 had no ova
of S. haematobium in their urine samples after 7 weeks of
treatment, which was an overall cure rate of 86%.
Parasitological egg count reduction of 85% after 7 weeks
of treatment was observed. The number of eggs for every
10 ml urine ranged from 1 to 1488 with overall geometric
mean of 19.95 eggs per 10 ml before treatment and thissex,age, haematuria and proteinuria in Dulshatalo
fection x2 p-value
s/10 ml) Heavy(≥50 eggs/10 ml) Total
38 146
10 51








48 197 20.12 0.003
47 169
1 28
48 197 7.66 0.006
47 172
1 25
48 197 6.44 0.01
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ric mean of 3.06 eggs per 10 ml after treatment (Table 2).
Haematuria and proteinuria before and after seven weeks
of treatment with PZQ
All of the study participants (N = 152) had haematuria
whereas 143 (94.07%) had proteinuria when examined
using reagent strip tests before treatment. The prevalence
of haematuria and proteinuria after 7 weeks of treatment
declined to 40.8% and 48.7%, respectively (Table 3).
Pre and post treatment symptoms
Pre-treatment symptoms profiles were recorded from all
of the study participants but only 65 out of 197 treated,
reported at 24 hours post treatment and of them, fifty
(76.92%) were male. All of the participants reported more
than one symptom both before and 24 hrs post treatment.
Straining, diarrhoea, fatigue, drowsiness, fever and
itching occurred with a higher frequency after treatment
than before treatment, while headache and nausea which
were common before treatment, declined. On the other
hand, all the study participants reported haematuria before
and 24 hours post treatment (Table 4).
Discussion
All of the study participants belonged to the same ethni-
city and religion and most have lived in the area since
birth. Macrohaematuria was a common phenomenon in
this community and it is indicative of high morbidity [8].
Our study revealed that the prevalence and the infection
intensity according to WHO is categorized as high and in-
dicates universal treatment is necessary to the communityTable 2 Prevalence and intensity of S. haematobium before a
sex, age and geometric mean egg count in Dulshatalo village
Variable Intensity of infection before treatment
Light (<50 Eggs/10 ml) Heavy (≥50 eggs/10









≥ 45 1 5
Total 108 44
GM(eggs/10 ml) 8.20 176.67irrespective of age, sex, infection status, or other social
characteristics [8].
In this study, a cure rate of 86.8% was found 7 weeks
post- treatment, which is comparable to the findings of
similar studies conducted in Cameroon [30], Zimbabwe
[31], north-east Ethiopia [25]. The egg count reduction
observed 7 weeks after treatment was 84.66%. This is
lower than those observed in Cameroon [30], Zimbabwe
[31], and north-east Ethiopia [25]. This might have been
due to the presence of pre-patent infections [33] and lack
of PZQ efficacy against the immature stages of schisto-
somes [16]. We haven’t determined the viability of ex-
creted eggs and this is one limitation of our study. Dead
eggs that may be present for months in the urine of
treated patients infected with S. haematobium [10] will
falsely decrease the egg reduction and cure rate results.
Higher cure rates were found in males than in females.
Females in this community are responsible for gold min-
ing,which exposes them to high water contact (for separ-
ating the gold out of the soil) which is infested with
cercaria of schistosomes. This may lead to existence of
pre-patent infections at the time of treatment. In
addition, school age children had high prevalence and
intensities of schistosome eggs and showed lower cure
rates than adults. Since the children had an increased
water contact due to different activities like swimming,
pre-patent infections may exist at the time of treatment,
which affects the cure and the egg reduction rates.
In response to treatment with single dose of praziquantel,
haematuria fell from 100% to 40.8% and proteinuria from
94.07% to 48.7% seven weeks post- treatment. Most studies
conducted have assessed effect of PZQ on haematuria and




ml) Total Light (<50 eggs/10 ml) Heavy (≥50 eggs/10 ml) Total
123 13 1 14
29 6 0 6
152 19 1 20
4 0 0 0
85 10 1 11
38 5 0 5
10 2 0 2
9 1 0 1
6 1 0 1
152 19 1 20
19.95 2.64 50 3.06
Table 3 Haematuria and proteinuria before and seven weeks after the administration of PZQ, Dulshatalo village,
western Ethiopia
Variable Before treatment After treatment
Haematuria (pos for Ova) Proteinuria (Pos for Ova) Haematuria (Pos for Ova) Proteinuria (Pos for Ova)
Sex Male 123(123) 115(115) 53(8) 57(7)
Female 29(29) 28(28) 9(4) 17(4)
Total 152(152) 143(143) 62(12) 74(11)
Age (Years)
< 5 4(4) 4(4) 2(0) 2(0)
5-14 85(85) 82(82) 35(7) 40(7)
15-24 38(38) 35(35) 19(4) 22(3)
25-34 10(10) 10(10) 2(0) 2(0)
35-44 9(9) 7(7) 2(0) 6(0)
≥ 45 6(6) 5(5) 2(1) 2(1)
Total 152(152) 143(143) 62(12) 74(11)
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haematuria from 75% to17% and proteinuria from 73% to
27% 12 months after treatment [36]. A study from Ghana
on the other hand has reported the reduction of haematuria
by 77% in children less than 15 years of age and by 68% in
adults at six month follow up [27].
Since all the residents of the village were Muslims and
the data were collected in Ramadan (fasting month),
most of them could not appear for interview on post-
treatment symptoms and this is the second limitation of
our study. But, the side effects reported in this study
were more or less consistent with those side effects
reported in other schistosome endemic areas [22,23,25,29].
Increased rates of straining, diarrhoea, fatigue, drowsiness,Table 4 Frequency of symptoms before and 24 hrs after treat
















Dysuria 0 0fever and itching were observed 24 hours after treat-
ment. On the other hand, uncommon side effects such
as joint pains, joint swellings, myalgia and peri-tibial/
ankle oedema were not reported in this study as they
were reported from Afar Region of Ethiopia in treat-
ment of S. haematobium infected patients [34] and in
treatment of S. mansoni [25] from north -east Ethiopia.
Most of the post treatment symptoms manifested soon
after drug therapy and the majority were mild and
short-lived. On the other hand, the presence and degree
of haematuria and proteinuria before treatment were
correlated with the presence of S.haeamtobium eggs
and count in urine, which is a similar finding with the
study conducted in Kenya [36].ment for S. haematobium with a single dose of PZQ,
24 hrs post treatment
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Though PZQ was used for long time at Dulshatalo vil-
lage for the treatment of schistosomiasis, the disease re-
mains high. This study has indicated that in a highly
endemic area with very high infection intensity, the cure
and the egg count reduction rates at the recommended
dose of 40 mg/kg were high. Mass chemotherapy to-
gether with the control of intermediate host snails and
their habitats should be integrated into primary health
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